Cetuximab biosimilar (CinnaGen)

西妥昔单抗生物类似药 (CinnaGen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCetuximab biosimilar (CinnaGen)
Drug Alias Name西妥昔单抗生物仿制药 (CinnaGen)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2017/01/01
Country/TerritoryIran
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCinnagen
China Registration ClassN/A

Develop Information

Active CompaniesCinnagen
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC06
Related LinksN/A